BOARD OF DIRECTORS
Chairman of Board
Chairman of Board
Alan Olsen was founder and President of Danek Medical, Inc. With more than $90 million in sales during the early 1990’s after merging with Sofamor, Sofamor Danek Group, a New York Stock Exchange (NYSE)-listed company, became the world’s largest supplier of implants, computer-assisted surgery products, and biologics for spinal surgery and neurosurgery. Medtronic, the world’s largest medical device company, acquired Sofamor Danek in January 1999.
Alan Olsen is Chairman of the Board of Atlas Spine, a spinal implant company. He has also been an active investor and director in six privately held companies, primarily in the medical device industries, which have either been acquired or are profitable operating businesses today. Mr. Olsen recently retired from the Board of Directors of Cyberonics, a NASDAQ-listed company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy System, which is FDA-approved for the treatments of epilepsy and treatment-resistant depression.
In addition to his service on corporate and private boards, Mr. Olsen has served as chairman or board member with eight charitable organizations focused on spinal cord injury, children’s advocacy for foster children and the arts over the past 10 years.
Director & co-founder
Director & Chief Executive Officer
Pierre Jérôme founded SpineGuard with Stéphane Bette in January 2009. Mr. Jérôme has 26 years of experience in the medical device industry, more than half in spine.
Prior to founding SpineGuard, Mr. Jérôme served as Executive Vice President Sales & Marketing for SpineVision, a privately-owned international company developing and marketing spinal devices. Between 1997 and 2005, Mr. Jérôme held various senior positions in sales, marketing and general management in both the US and Europe with Boston Scientific Corp., a company focused on less-invasive technologies across the medical industry.
Prior to joining BSC, he served five years with Sofamor Danek, a pioneering spine company which has since been integrated by Medtronic, today’s spine leader. While at Sofamor Danek, Mr. Jérôme held several marketing positions, including European Marketing Director.
Mr. Jérôme holds a Master degree in Management from the INSEEC School of Business Bordeaux, France.
Observer, co-founder and Chief Executive Officer
Observer & Chief Technical Officer
Mr. Bette brings more than 18 years of R&D and general management experience in the Spine industry.
Prior to founding SpineGuard, Mr. Bette was a member of the foundational team of SpineVision, a privately-owned international company focused on the development and marketing of spinal devices, where he served for 10 years at various positions of increasing responsibilities from R&D Project Management to VP of R&D and finally US General Manager. Mr. Bette began his career in 1996 as R&D Project Manager with Sofamor Danek, a pioneering spine company which has since been integrated by Medtronic, today’s spine leader, where he developed a scoliosis system.
Mr. Bette received a Master degree in Mechanical Engineering from ENSAM, France and a Post-graduate Degree in Biomechanics from LBM in Paris, France.
Director & co-Inventor
Maurice Bourlion is the co-inventor of pediguard® and co-inventor of Electroconductive shockwave lithotripsy. Today he is Professor at Jean Monnet University in Saint Etienne France. He is also Board Member of SpineGuard and member of its Scientific Advisory Board. Formerly Maurice Bourlion was Executive Vice President for SpineVision® group and General Manager of its North American subsidiary in San Francisco (California, USA). Beside his international experience of Marketing for HighTech products Maurice’s scientific expertise is broad and includes pressure transducers (he has directed the study “Maintenance of graft compression in adult cervical spine”), ultrasounds, shock waves, electrophysiology in particular electro stimulation.
Prior to this Maurice was Business Development Director at Medtronic and successfully launched incontinence pacing products and sleep diseases devices in Europe. Before that he was involved in the international development and the successful launch of Extracorporeal Lithotripters of Technomed International group and held several positions as project and product manager. He started his career in the basic research group of Dowell Schlumberger where he participated to design experimental set-up for measuring fluid flow in heterogeneous media.
Maurice Bourlion holds a biomedical engineering degree from Ecole Nationale Supérieure d’Electronique et de ses Applications (ENSEA) and a University Degree in Electronics. He is also Certified Professor at the college of electrical engineering and computer science. He is author of more than 40 scientific publications and listed as inventor for 18 patents.
Thomas Balland is an investment director and specializes in software, wireless and medical devices investments. He assesses investment opportunities, conducts due diligence, leads negotiations and transaction closings, and actively monitors portfolio companies. Thomas currently serves on the boards of Aupeo, Club Cooee, CMC Biologics, Ingen BioSciences, Navx, SpineGuard, SpineVision, SymbioFCell and Traqueur (Alternext: ALTRA). He is responsible for investments in Paion (Frankfurt Stock Exchange: PA8).
Thomas sat on the Board of Innoven portfolio company gate5 AG, which was sold to Nokia in 2006. He was also involved with Digiplug, sold to Faith (Tokyo Stock Exchange: 4295) and ProStrakan (listed on the LSE, and then acquired by Kirin in 2011). Thomas has over 10 years of venture capital investment experience. Prior to joining Innoven in 2002, he held various positions with firms such as Mars Inc., Up&Up and Vivendi. Thomas received dual degrees in engineering and finance from INSA Lyon and ESCP-EAP respectively.
CEO & Managing Partner Ibionext
Alexia Perouse is doubly qualified in Neurosciences and Management of Enterprises and has worked more than 20 years in the development of public or private innovative companies.
She started her career in the biotechnology field working as an analyst for Chiron Vaccines and Parteurop Développement before joining the sector of Private Equity in 1999 at Sofinnova Partners then at Omnes Capital in 2005. As a partner, Alexia was in charge of the venture capital portfolio (representing € 330M). Specifically, she has developed the medical device (« medtech ») and connected health portfolios.
She has led investments in over ten start-ups (Gecko Biomedical, EyeTechCare…) and played an active governing role as Director. She also pursued several merger and acquisitions such as Biolipox – Orexo, Mutabilis, Pharma Omnium International, Fovea Pharmaceuticals / Sanofi-Aventis, Circulite Inc / Heartware Inc., and several IPO’s such as Eos Imaging (EOSI), Stentys (STNT), SpineGuard (ALSGD), SuperSonic Image (SSI), Pixium Vision (PIX), and Cellnovo (CNV).
Since December 2015, she has been the CEO & Managing Partner at iBionext: a French company specialized in the support of medical innovative and disruptive technologies from creation to growth.
Alexia Perouse also sits on the board of directors of SuperSonic Imagine: an innovative, international company specialized in medical imaging.
Joey Mason joined Delta Partners in 2003, specialising in Life Science investments. He serves on the boards of Genable, Glysure, Miracor and SpineGuard. Having trained as a doctor, Joey spent five years as an investment banker in the Health Care market with Morgan Stanley International and Technomark in London. From 1995 until 1999 he was Director of Corporate Development at Biotrin Holdings plc, an Irish biotechnology company backed by Delta Partners and other VCs. In 2000 he co-founded and managed Eumom Ltd, a marketing services business which operates websites for pregnant women in Germany, Ireland, Switzerland and the UK. He is a director of Eumom Marketing Ltd. A medical graduate of Trinity College, Dublin, he is a Fellow of the RSA.
Pierre Guyot has 30 years of experience in the international healthcare industry. He has acquired extensive experience working with global industry leaders both within public companies as well as within Private Equity sectors. During his career Pierre has lived in five countries and on three continents.
From 2007 to 2014, Pierre was the CEO and a member of the board of directors of the Swedish company Mölnlycke Health Care. They are a world leading manufacturer of single-use surgical and wound care products and services provider to the health care sector. Mölnlycke is present in over 40 countries and has revenue of $1.5 billion. From 2006 to 2007, Pierre served as President of the Wound Care division. Prior to joining Mölnlycke Health Care, from 1987 to 2005, Pierre served in various capacities in Sales & Marketing and C-level EMEA positions with American companies such as Becton Dickinson, Johnson & Johnson, and Boston Scientific.
Currently, Pierre serves as a Director of Permobil AB, a worldwide leader in providing mobility solutions for complex rehabilitation, and of Peters Surgical, a European leader for Surgical Wound Closure.
Pierre Guyot holds a degree from the Institut Supérieur de Gestion (France) and a MBA from the University of San Francisco.
Board Observer representing IPF Partners
Board Observer representing IPF Partners
Edouard Guillet is a co-founder and managing director of IPF Partners, a leading alternative financing provider focused on the European healthcare sector. Edouard has over 17 years of experience in the healthcare industry. He previously led the Hepatitis and Anti-Fungal Business Unit of Gilead Sciences in France, the leading virology biotech company, after being Gilead Sciences’ Marketing Director, a senior Marketing Executive at Medtronic, the global leader in medical technologies and a Principal at the Boston Consulting Group, a leading strategic consultancy.
Edouard Guillet started his career in investment banking with CCF (now HSBC). He holds an MsC from HEC in Paris.
IPF Partners manages investments funds that invest directly in emerging, commercial-stage European pharma/biotech, medtech, diagnostics and e-health companies. IPF provides customised, low- to non-dilutive debt financing to market leading healthcare companies. Typical investments ranges from €5-30m over 3-7 years duration.